ATAI

3.69

3.40% -0.13

Dopo l'orario di chiusura: 3.68 -0.010 -0.27%

Ataibeckley Inc (ATAI)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$3.82

Aprire:

$3.75

Volume 24 ore:

4.17M

Relative Volume:

1.01

Capitalizzazione di mercato:

$1.34B

Reddito:

$3.06M

Utile/perdita netta:

$-141.62M

Rapporto P/E:

-5.0184

EPS:

-0.7353

Flusso di cassa netto:

$-78.67M

1 W Prestazione:

+8.85%

1M Prestazione:

+3.36%

6M Prestazione:

-20.30%

1 anno Prestazione:

+165.47%

Intervallo 1D:

$3.65

$3.90

Intervallo di 1 settimana:

$3.38

$4.25

Portata 52W:

$1.15

$6.75

Ataibeckley Inc Stock (ATAI) Company Profile

Nome

Ataibeckley Inc

Settore

Healthcare (1116)

Industria

Biotechnology (621)

Telefono

49 89 2153 9035

Indirizzo

PROF. J.H. BAVINCKLAAN 7, AMSTELVEEN

Dipendente

Cinguettio

Prossima data di guadagno

2024-12-11

Ultimi documenti SEC

ATAI's Discussions on Twitter

Compare ATAI vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ATAI Ataibeckley Inc	3.69	1.34B	3.06M	-141.62M	-78.67M	-0.7353
VRTX Vertex Pharmaceuticals Inc	469.34	119.23B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.77	78.84B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	700.45	43.35B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.41	41.57B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.05	31.51B	5.36B	287.73M	924.18M	2.5229

Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-20	Iniziato	Guggenheim	Buy
2025-10-13	Iniziato	Needham	Buy
2025-07-29	Iniziato	Oppenheimer	Outperform
2024-11-18	Reiterato	H.C. Wainwright	Buy
2024-04-03	Aggiornamento	Maxim Group	Hold → Buy
2022-11-01	Iniziato	Loop Capital	Buy
2021-11-30	Iniziato	Maxim Group	Buy
2021-11-11	Iniziato	ROTH Capital	Buy
2021-10-18	Iniziato	H.C. Wainwright	Buy
2021-09-01	Iniziato	Jefferies	Buy
2021-07-13	Iniziato	Berenberg	Buy
2021-07-13	Iniziato	Canaccord Genuity	Buy
2021-07-13	Iniziato	Cantor Fitzgerald	Buy
2021-07-13	Iniziato	Citigroup	Buy
2021-07-13	Iniziato	Cowen	Outperform
2021-07-13	Iniziato	Credit Suisse	Outperform
2021-07-13	Iniziato	RBC Capital Mkts	Sector Perform
2021-07-08	Iniziato	Aegis Capital	Buy

Mostra tutto

Ataibeckley Inc Borsa (ATAI) Ultime notizie

Mar 13, 2026

AtaiBeckley Is Said to Explore Options for Main Psychedelic Drug - MSN

Mar 13, 2026

Mar 12, 2026

AtaiBeckley plans Phase 3 trials for depression treatment in Q2 By Investing.com - Investing.com Nigeria

Mar 12, 2026

Why AtaiBeckley (ATAI) Is Up 10.0% After FDA Backs BPL-003 Phase 3 Depression Trials - simplywall.st

Mar 12, 2026

Mar 11, 2026

Pα+ Psychedelic Bulletin #221: Helus Reports Murky Phase 2a Results; AtaiBeckley Says R-MDMA Met Safety Goal in SAD, Details Phase 3 Design for 5-MeO-DMT in TRD; Psilocybin for Smoking Cessation Study Published - Psychedelic Alpha

Mar 11, 2026

ATAI: Short-duration psychedelic therapies show strong efficacy and commercial promise - TradingView

Mar 11, 2026

ATAI: Short-duration psychedelic therapies show strong efficacy and commercial promise in mental health - TradingView

Mar 11, 2026

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting, AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day - marketscreener.com

Mar 11, 2026

H.C. Wainwright Maintains Buy on ATAI Atai Beckley N.V Mar 2026 - Meyka

Mar 11, 2026

Analysts Are Bullish on These Healthcare Stocks: Atai Beckley N.V. (ATAI), BridgeBio Oncology Therapeutics (BBOT) - The Globe and Mail

Mar 11, 2026

Mar 10, 2026

Small cap wrap: Immunic, AtaiBeckley, Standard Uranium, Trust Stamp… - Proactive Investors

Mar 10, 2026

AtaiBeckley Social Anxiety Treatment A Game-Changer: AnalystsAtaiBeckley (NASDAQ:ATAI) - Benzinga

Mar 10, 2026

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day - Investing News Network

Mar 10, 2026

AtaiBeckley outlines plans for Phase 3 trials of BPL-003 in treatment-resistant depression at Investor Day - Yahoo Finance

Mar 10, 2026

H.C. Wainwright reiterates atai Life Sciences stock rating at buy By Investing.com - Investing.com Nigeria

Mar 10, 2026

H.C. Wainwright reiterates atai Life Sciences stock rating at buy - Investing.com India

Mar 10, 2026

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Atai Beckley N.V. (ATAI) and Artivion (AORT) - The Globe and Mail

Mar 10, 2026

Atai Beckley advancing BPL-003 nasal spray towards Phase 3 after FDA meeting - TipRanks

Mar 10, 2026

AtaiBeckley Inc. Advances BPL-003 toward Phase 3 Trials for Treatment-Resistant Depression Following Positive Phase 2b Results - Quiver Quantitative

Mar 10, 2026

AtaiBeckley nasal spray for hard-to-treat depression eyes 2026 trials - Stock Titan

Mar 10, 2026

Mar 09, 2026

Assessing Atai (ATAI) Valuation After FDA Backing For BPL-003 And Positive EMP-01 Trial Results - simplywall.st

Mar 09, 2026

AtaiBeckley Exploring Potential Sale, Partnership for Psychedelic Drug Candidate - marketscreener.com

Mar 09, 2026

Atai Life Sciences Stock Poised for Gains Amid New FDA Trials Approval - timothysykes.com

Mar 09, 2026

FDA Supports AtaiBeckley’s New Depression Treatment Trials - StocksToTrade

Mar 09, 2026

AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal - Psychedelic Alpha

Mar 09, 2026

AtaiBeckley’s FDA Backing And Trial Data Reframe Mental Health Upside And Risk - Yahoo Finance

Mar 09, 2026

4 Analysts Have This To Say About AtaiBeckley - Benzinga

Mar 09, 2026

AtaiBeckley Files For Mixed Shelf Offering - TradingView

Mar 09, 2026